X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ABBOTT INDIA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ABBOTT INDIA DISHMAN PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 25.1 40.2 62.4% View Chart
P/BV x 3.3 10.3 32.4% View Chart
Dividend Yield % 0.7 0.7 99.4%  

Financials

 DISHMAN PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ABBOTT INDIA
Mar-18
DISHMAN PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3746,110 6.1%   
Low Rs1293,996 3.2%   
Sales per share (Unadj.) Rs197.81,552.2 12.7%  
Earnings per share (Unadj.) Rs21.2188.8 11.2%  
Cash flow per share (Unadj.) Rs34.7196.4 17.7%  
Dividends per share (Unadj.) Rs2.0055.00 3.6%  
Dividend yield (eoy) %0.81.1 73.0%  
Book value per share (Unadj.) Rs179.9796.6 22.6%  
Shares outstanding (eoy) m80.6921.25 379.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.3 39.1%   
Avg P/E ratio x11.926.8 44.3%  
P/CF ratio (eoy) x7.225.7 28.2%  
Price / Book Value ratio x1.46.3 22.1%  
Dividend payout %9.429.1 32.4%   
Avg Mkt Cap Rs m20,306107,376 18.9%   
No. of employees `0000.83.3 25.0%   
Total wages/salary Rs m5,3553,937 136.0%   
Avg. sales/employee Rs Th19,252.79,929.3 193.9%   
Avg. wages/employee Rs Th6,459.51,185.1 545.1%   
Avg. net profit/employee Rs Th2,064.11,207.7 170.9%   
INCOME DATA
Net Sales Rs m15,96132,985 48.4%  
Other income Rs m2651,170 22.7%   
Total revenues Rs m16,22634,155 47.5%   
Gross profit Rs m4,1035,245 78.2%  
Depreciation Rs m1,091162 673.6%   
Interest Rs m94438 2,472.3%   
Profit before tax Rs m2,3346,215 37.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,203 28.3%   
Profit after tax Rs m1,7114,012 42.6%  
Gross profit margin %25.715.9 161.7%  
Effective tax rate %26.735.4 75.4%   
Net profit margin %10.712.2 88.1%  
BALANCE SHEET DATA
Current assets Rs m11,01822,655 48.6%   
Current liabilities Rs m9,5176,681 142.5%   
Net working cap to sales %9.448.4 19.4%  
Current ratio x1.23.4 34.1%  
Inventory Days Days11065 170.6%  
Debtors Days Days3529 119.5%  
Net fixed assets Rs m16,304835 1,951.5%   
Share capital Rs m161213 76.0%   
"Free" reserves Rs m12,90716,715 77.2%   
Net worth Rs m14,51616,928 85.8%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80524,162 123.4%  
Interest coverage x3.5163.7 2.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.4 39.2%   
Return on assets %8.916.8 53.1%  
Return on equity %11.823.7 49.7%  
Return on capital %17.536.9 47.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,952369 1,343.5%   
Fx outflow Rs m6973,807 18.3%   
Net fx Rs m4,255-3,438 -123.8%   
CASH FLOW
From Operations Rs m2,7861,527 182.5%  
From Investments Rs m-1,529-2,148 71.2%  
From Financial Activity Rs m-941-1,024 91.9%  
Net Cashflow Rs m316-1,646 -19.2%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 7.9 46.8%  
FIIs % 12.7 0.1 12,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.1 129.2%  
Shareholders   46,261 18,270 253.2%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  SUVEN LIFE  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS